Ditchcarbon
  • Customers
  1. Organizations
  2. Kyorin Pharmaceutical
Public Profile
Pharmaceutical Preparation Manufacturing
JP
updated 5 days ago

Kyorin Pharmaceutical

Company website

Kyorin Pharmaceutical Co., Ltd., commonly referred to as Kyorin, is a prominent player in the pharmaceutical industry, headquartered in Tokyo, Japan. Established in 1923, the company has made significant strides in research and development, particularly in the fields of respiratory and infectious diseases, as well as urology. Kyorin is renowned for its innovative products, including prescription medications and over-the-counter solutions, which are distinguished by their efficacy and safety profiles. The company has achieved notable market presence, particularly in Japan and other key regions across Asia. With a commitment to advancing healthcare, Kyorin continues to focus on developing unique therapies that address unmet medical needs, solidifying its position as a trusted name in the pharmaceutical sector.

DitchCarbon Score

How does Kyorin Pharmaceutical's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

35

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

28

Industry Benchmark

Kyorin Pharmaceutical's score of 35 is higher than 60% of the industry. This can give you a sense of how well the company is doing compared to its peers.

60%

Let us know if this data was useful to you

Kyorin Pharmaceutical's reported carbon emissions

In 2023, Kyorin Pharmaceutical reported total carbon emissions of approximately 41,812,000 kg CO2e. This figure includes Scope 1 emissions of about 12,895,000 kg CO2e, Scope 2 emissions of around 12,110,000 kg CO2e, and Scope 3 emissions totalling approximately 16,807,000 kg CO2e. The Scope 3 emissions breakdown reveals significant contributions from capital goods (about 5,263,000 kg CO2e), purchased goods and services (approximately 6,233,000 kg CO2e), and employee commuting (around 977,000 kg CO2e). Kyorin Pharmaceutical has not publicly disclosed specific reduction targets or initiatives under the Science Based Targets initiative (SBTi) or other climate pledges. The company’s emissions data reflects a commitment to transparency, with disclosures covering all relevant scopes. Over the past few years, Kyorin's emissions have shown fluctuations, with total Scope 1 and 2 emissions recorded at approximately 26,727,000 kg CO2e in 2022, down from about 27,594,000 kg CO2e in 2021 and 29,074,000 kg CO2e in 2020. This trend indicates a potential focus on reducing operational emissions, although specific reduction strategies have not been detailed. Kyorin Pharmaceutical's emissions data is not cascaded from any parent organisation, ensuring that the reported figures are solely reflective of its own operations. The company continues to navigate the complexities of carbon management within the pharmaceutical industry, aiming for improved sustainability practices in the future.

Unlock detailed emissions data

Access structured emissions data, company-specific emission factors, and source documents

201520192020202120222023
Scope 1
-
-
-
-
-
00,000,000
Scope 2
-
-
-
-
-
00,000,000
Scope 3
-
-
-
-
-
00,000,000

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Kyorin Pharmaceutical's primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Kyorin Pharmaceutical is in JP, which has a low grid carbon intensity relative to other regions.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

Kyorin Pharmaceutical is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Similar Organizations

Codex

HU
•
Pharmaceutical Preparation Manufacturing
Updated 10 days ago

Glaxosmithkline

GB
•
Pharmaceutical Preparation Manufacturing
Updated about 6 hours ago

Urovant Sciences Ltd.

GB
•
Pharmaceutical Preparation Manufacturing
Updated 10 days ago

Teva Pharmaceuticals

IL
•
Pharmaceutical Preparation Manufacturing
Updated about 6 hours ago

Pfizer

US
•
Pharmaceutical Preparation Manufacturing
Updated about 6 hours ago

Merck And Co

US
•
Pharmaceutical Preparation Manufacturing
Updated about 6 hours ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers

Ditchcarbon
v250804.3
enquiries@ditchcarbon.com+44 203 475 7875Ditch Carbon Ltd167-169 Great Portland StreetLondon W1W 5PF
Verified byUL Verified
Partnered withCDP
ProductPortalDataDocumentationIntegrationsChangelogPricing
SolutionsProcurement teamsSustainability teamsPlatform ownersCarbon accountants
ResourcesMethodologyBlogFAQOrganizationsIndustriesSBTI APITrust Centre
AboutTeamCareersLicense AgreementPrivacy